Hemostasis - Partnership Meeting Breakout Session

On May 24th and May 25th, we had the pleasure to spend the days together sharing Hemostasis Diagnostics updates.

We started the sessions with the roadmap of the next few years of the Hemostasis Strategy, delivered by Ken Huffenus, Director Worldwide Hemostasis Marketing at Werfen. He shared with the audience the strategy of stronger emphasis on specialization of our services through enhanced digital integration along with the launch of a new family of instruments and the full release of the flagship ACL TOP 970 CL as part of a complete ACL TOP 70 Series family.

We followed that up with a complete overview of the performance of Hemostasis in EEMEA, with the strengthening of our leadership position driven by a consistent demand for our analyzers and the strong performance of our reagent families beyond the COVID 19 demand, with continued demand for D-Dimer assays, inherited bleeding disorders (Hemophilia and VWD), FXIII, Heparin, Antithrombin, HIT and ADAMTS13.

We also shared the success story from Greece on the reintroduction of HemosIL ReadiPlasTin, a major milestone in our offering of liquid ready to use reagent and for our routine reagent portfolio.

We also launched a complete package of resources to support D-Dimer Education in our markets. This includes a set of newly released material along with recently created content.

hem 17thissue 2

We concluded our reagent section with a success story from Finland on the introduction of our HemosIL AcuStar ADAMTS13 Activity highlighting the key value drivers of adoption of the assay and the need of transparency while accompanying the customer in their adoption phase.

A key component of the Hemostasis Sessions were competition updates and the breakout session on competing with the CN Analyzer. 2023 marks an eventful year for Hemostasis where strategic moves and new product launches. Alberto Gomez, Worldwide Group Product Manager Hemostasis, shared the key competitive information and sustained the discussion on the possible impact and relevance of such moves.

We started on May 25th the day with a block of content on HemoHub Intelligent Data Manager with an overview of the core features (instrument management, results management, and quality management) and the impact on the tender process. We followed that up with a review of key specialized features of HemoHub like the implementation of algorithms or the uncertainty calculations that provide further specialization in the hemostasis lab. We also had the opportunity to have two talks on regional experiences. The first was from Silvio Castagni, Group Product Manager Hemostasis, Werfen in Italy who shared the role HemoHub plays as part of the Hemostasis solution in terms of customer lifecycle management and the impact of IT and connectivity in the market. The second was from the Russia/CIS team on the successful installation of HemoHub in Kazakhstan with the largest installation in EEMEA of a 26 ACL TOP 50 Series in 15 Laboratories across the country connected through HemoHub.

hem 17thissue 3

Our final block of content included an extensive review of our consultant and specialized approach to supporting our customers with workflow assessment and support. We reviewed the processes, tools and impact of the workflow assessment on customer needs while maintaining specialization in Hemostasis.

In addition to the workflow assessment, we had breakout sessions to work on a workflow exercize and showcase the benefit of utilizing our Virtual Reality tool for HemoCell.

hem 17thissue 4

These activities and sessions were a very good build up for the success story of the first HemoCell installation in Poland in a private laboratory chain.

hem 17thissue 5

Stay Safe and Take Care of Each Other.

Hemostasis Marketing Team, EEMEA

Last modified on Thursday, 08 June 2023 06:16

 

All rights reserved. © werfen.com

Get in touch

with the EEMEA team:

eemea@werfen.com

 

werfenplain

Issues

Go to top